Hepatitis C virus: a hidden epidemic
Market landscape 2017

HCV IS ON THE RISE

SIX KEY OBSTACLES TO TACKLING HCV

1. LACK OF FUNDING
5/29 countries surveyed have dedicated national HCV budget sufficient to meet or exceed the WHO 2020 targets.

2. LIMITED LAB NETWORKS
Limited laboratory networks negatively impact the scale up of HCV diagnostics and treatment in many high-burden countries.

3. TOO FEW HEALTHCARE WORKERS
Few frontline healthcare workers are assessing patients for risk of HCV and referring for appropriate diagnosis.

4. INSUFFICIENT DATA
Most countries do not track the volume or yields of screening or viral load tests at a national level, impeding the development of well-informed country strategies, the proper use of diagnostic commodities, and effective price negotiations with suppliers.

5. LACK OF STRATEGY
Few countries have concrete diagnostic targets or scale-up plans for HCV that operationalize the WHO HCV diagnosis targets.

6. LOW PUBLIC AWARENESS OF HCV
Education and awareness programmes in-country are critical to improving the general public’s knowledge and reduce stigma associated with HCV, leading to increased demand for testing and improved case-finding.

"Every country in the world has committed to eliminating viral hepatitis by 2030 [but] we are missing a crucial piece of the puzzle. Of the 325 million people living with viral hepatitis, 300 million are still unaware. Without finding the undiagnosed and linking them to care, elimination will remain nothing but a pipe dream." — Raquel Peck, World Hepatitis Alliance CEO

WHO 2015–2030 Viral Hepatitis Strategy Aims for:

- 90% of patients diagnosed
- 80% receiving treatment
- 90% reduction in incidence
- 65% reduction in mortality

If implemented, this would avert 2.1m HCV-associated deaths

Total need for screening tests (either lab-based immunoassays or RDTs) over the next 5 years for high-burden LMICs is estimated to be 826 million tests.

Total need for confirmation and monitoring tests over the next 5 years for high-burden LMICs is estimated at 31 million tests.

Data from a 2017 market intelligence analysis of HCV diagnostic products covering 29 LMICs, providing 5-year forecasts on need and demand for screening, confirmatory and monitoring tests, and outlining the elements driving the projections and the factors that will allow countries to diagnose more patients.


Report developed in collaboration with CHAI and with support from Unitaid